TQB 3728
Alternative Names: TQB-3728Latest Information Update: 18 Jul 2024
At a glance
- Originator Chia Tai Tianqing Pharmaceutical Group
- Class Antineoplastics; Small molecules
- Mechanism of Action Inhibitor of apoptosis protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Lymphoma; Solid tumours
- No development reported Cancer
Most Recent Events
- 31 May 2024 TQB 3728 is still in phase I trials for Solid tumours and Lymphoma in China (PO)
- 31 May 2024 Efficacy, adverse events, pharmacokinetics and pharmacodynamics data from a phase I trial in Solid tumours presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 28 Nov 2023 No recent reports of development identified for phase-I development in Lymphoma(In the elderly, Late-stage disease, Refractory metastatic disease, Second-line therapy or greater, In adults) in China (PO, Tablet)